Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
11.06
+0.04 (0.32%)
Jul 28, 2026, 4:00 PM EDT - Market closed
Oculis Holding AG Employees
Oculis Holding AG had 60 employees as of December 31, 2025. The number of employees increased by 11 or 22.45% compared to the previous year.
Employees
60
Change (1Y)
11
Growth (1Y)
22.45%
Revenue / Employee
$23,334
Profits / Employee
-$1,965,541
Market Cap
667.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 60 | 11 | 22.45% |
| Dec 31, 2024 | 49 | 13 | 36.11% |
| Dec 31, 2023 | 36 | 8 | 28.57% |
| Dec 31, 2022 | 28 | - | - |
| Sep 30, 2022 | 32 | - | - |
| Jun 30, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Replimune Group | 465 |
| Rigel Pharmaceuticals | 174 |
| Neurogene | 131 |
| BridgeBio Oncology Therapeutics | 106 |
| SpyGlass Pharma | 68 |
| Crescent Biopharma | 55 |
| Candel Therapeutics | 55 |
OCS News
- 20 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 27 days ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
- 6 weeks ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire
- 7 weeks ago - Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - GlobeNewsWire
- 7 weeks ago - Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Oculis Holding AG Slides: Study update presentation - Filings
- 7 weeks ago - Oculis price target lowered to $23 from $42 at JPMorgan - TheFly